Scientific publications
Cabergoline for Cushing's disease: A case report
Pascual-Corrales E (1), Tomás Velázquez A (1), Zubieta JL (2), Salvador J (3), Galofré JC (4).
(1) Department of Endocrinology and Nutrition, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain.
(2) Department of Radiology, Clínica Universidad de Navarra, University of NavarraPamplona, Spain.
(3) Department of Endocrinology and Nutrition, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
(4) Department of Endocrinology and Nutrition, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain; Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain.
Cushing’s syndrome results from a prolonged exposure to excessive concentrations of free circulating glucocorticoids. ACTH dependent Cushing’s syndrome or Cushing’s disease (CD) represents approximately 80---85% of the total cases, and around 80% of them correspond to ACTH secreting pituitary adenomas.
Transesphenoidal surgery remains the first line of treatment for CD.1 Other therapeutic approaches such as medical treatment, pituitary radiotherapy or bilateral adrenalectomy constitute the second-line treatment, and are normally indicated in case of surgical failure.
CITATION Endocrinol Nutr. 2015 Dec;62(10):516-8. doi: 10.1016/j.endonu.2015.07.002
